Key facts
- Octave Bioscience’s last known valuation is $143.0M (Jul 2023).
- It has raised $129.2M across 5 recorded rounds; the latest was Early Stage VC ($31.8M) in Mar 2025.
- Notable investors include European Innovation Council, Kleiner Perkins, S32, Deerfield Management, Casdin Capital — 18 tracked in total.
- Octave Bioscience has filed 5 Form Ds with the SEC since 2017, most recently Mar 2025 ($31.8M sold to 20 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 5 rounds
- ·The complete investor list — 18 names
- ·Watchlist + deal alerts for Octave Bioscience
Funding rounds
5 roundsAbout Octave Bioscience
Operator of a biomarker-driven precision medicine company intended to improve monitoring and treatment decisions for neurodegenerative diseases. The company offers comprehensive biomarker testing and data analytics capabilities, enabling neurologists and patients managing Multiple Sclerosis and Parkinson's disease to gain objective insights that support informed care decisions and improved patient outcomes.
- Sector
- Healthcare
- HQ
- Menlo Park, CA, United States
- Founded
- 2014
- Employees
- 72
- Website
- octavebio.com/
- Ownership
- Privately Held (backing)
Octave Bioscience doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Octave Bioscience shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Octave Bioscience in its N-PORT filings yet. We sweep new filings monthly.